NRX Pharmaceuticals (NRXP) Other Accumulated Expenses (2020 - 2026)

NRX Pharmaceuticals (NRXP) has 7 years of Other Accumulated Expenses data on file, last reported at $69000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 64.8% year-over-year to $69000.0 in Q1 2026; TTM through Mar 2026 was $69000.0, a 64.8% decrease from a year earlier, with the FY2025 full-year figure at $2000.0, down 99.57% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $69000.0, up from $2000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for NRXP reached as high as $1.6 million in Q3 2022 and fell as low as $2000.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $537647.1 across 5 years, with a median of $300000.0 in 2022.
• Across the five-year window, Other Accumulated Expenses jumped 480.25% in 2024 and plunged 99.57% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $974000.0 in 2022, then tumbled by 91.68% to $81000.0 in 2023, then soared by 480.25% to $470000.0 in 2024, then plunged by 99.57% to $2000.0 in 2025, then soared by 3350.0% to $69000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $69000.0 in Q1 2026, $2000.0 in Q4 2025, and $98000.0 in Q3 2025.